share_log

信達生物：內幕消息公告－2023年第四季度產品收入的最新消息

INNOVENT BIO: INSIDE INFORMATION ANNOUNCEMENT - UPDATE ON THE COMPANY''S PRODUCT REVENUE IN THE FOURTH QUARTER OF 2023

香港交易所 ·  Feb 6 17:19
Summary by Futu AI
信達生物製藥有限公司（「信達生物」）於2024年2月6日發布內幕消息，公告其2023年第四季度產品收入超過人民幣16億元，同比增長超65%。公司表示，這一強勁增長得益於達伯舒®（信迪利單抗注射液）等產品的市場領先地位進一步加強，以及產品組合的多元化。信達生物在腫瘤領域及心血管、代謝、自身免疫、眼科等領域的產品線持續豐富，並穩步推進商業化佈局。公司的兩款創新腫瘤靶向藥物IBI-344和IBI-351的新藥上市申請獲得優先審評資格。目前，信達生物已有十款產品獲批上市，並有多個新藥品種處於不同階段的臨床研究中。公司強調，未經外聘核數師審核或審閱的財務資料僅供投資者參考，並非購買或出售證券的要約。
信達生物製藥有限公司（「信達生物」）於2024年2月6日發布內幕消息，公告其2023年第四季度產品收入超過人民幣16億元，同比增長超65%。公司表示，這一強勁增長得益於達伯舒®（信迪利單抗注射液）等產品的市場領先地位進一步加強，以及產品組合的多元化。信達生物在腫瘤領域及心血管、代謝、自身免疫、眼科等領域的產品線持續豐富，並穩步推進商業化佈局。公司的兩款創新腫瘤靶向藥物IBI-344和IBI-351的新藥上市申請獲得優先審評資格。目前，信達生物已有十款產品獲批上市，並有多個新藥品種處於不同階段的臨床研究中。公司強調，未經外聘核數師審核或審閱的財務資料僅供投資者參考，並非購買或出售證券的要約。
SINDA BIOPHARMACEUTICAL CO., LTD. (“SINDA BIO”) RELEASED AN INSIDE STATEMENT ON FEBRUARY 6, 2024, ANNOUNCING THAT ITS FOURTH QUARTER PRODUCT REVENUE IN 2023 EXCEEDED RMB16 BILLION, AN INCREASE OF MORE THAN 65% YEAR-ON-YEAR. The company said this strong growth was driven by a further strengthening of its market leadership for products such as Dabersho® (Cindlyone Anti-Injection), as well as a diversification of its product portfolio. SindaBio continues to expand its product lines in the fields of oncology and cardiovascular, metabolism, autoimmune, ophthalmology, etc., and is steadily advancing commercialization. The Company's two innovative tumor-targeting drugs, IBI-344 and IBI-351, are eligible for priority review. Currently, Sinda Biologics has ten approved products and several new drug strains are in clinical trials at different stages. THE COMPANY EMPHASIZES THAT FINANCIAL INFORMATION NOT AUDITED OR REVIEWED BY AN EXTERNAL AUDITOR IS FOR INVESTOR REFERENCE ONLY AND IS NOT AN OFFER TO BUY OR SELL SECURITIES.
SINDA BIOPHARMACEUTICAL CO., LTD. (“SINDA BIO”) RELEASED AN INSIDE STATEMENT ON FEBRUARY 6, 2024, ANNOUNCING THAT ITS FOURTH QUARTER PRODUCT REVENUE IN 2023 EXCEEDED RMB16 BILLION, AN INCREASE OF MORE THAN 65% YEAR-ON-YEAR. The company said this strong growth was driven by a further strengthening of its market leadership for products such as Dabersho® (Cindlyone Anti-Injection), as well as a diversification of its product portfolio. SindaBio continues to expand its product lines in the fields of oncology and cardiovascular, metabolism, autoimmune, ophthalmology, etc., and is steadily advancing commercialization. The Company's two innovative tumor-targeting drugs, IBI-344 and IBI-351, are eligible for priority review. Currently, Sinda Biologics has ten approved products and several new drug strains are in clinical trials at different stages. THE COMPANY EMPHASIZES THAT FINANCIAL INFORMATION NOT AUDITED OR REVIEWED BY AN EXTERNAL AUDITOR IS FOR INVESTOR REFERENCE ONLY AND IS NOT AN OFFER TO BUY OR SELL SECURITIES.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.